Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review)

Chen, Chao; Tang, Xiaohuan; Liu, Yuanda; Zhu, Jiaming; Liu, Jingjing

doi:10.3892/ijo.2019.4751

Cited by 23 publications

(19 citation statements)

References 173 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, lncRNAs utilized as biomarkers for assessing the prognosis of cancer patients or as target molecules for the development of emerging specifically targeted drugs have been widely pursued [ 48 ]. Presently, many studies focus on the interactions between lncRNAs and GC resistance, and most of them mainly address multidrug resistance, especially resistance to doxorubicin, cisplatin, and fluorouracil [ 91 ]. It has been reported in many studies that lncRNAs induce drug resistance by regulating DNA damage and the cell cycle, thereby affecting drug transport systems, interfering with drug metabolism, disrupting tumor cell apoptosis, mediating the EMT process, and so on [ 92 ].…”

Section: Treatment Strategies For Gcmentioning

confidence: 99%

[Retracted] Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer

Sun

Jiang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Gastric cancer (GC) is the second leading cause of cancer mortality and the fourth most commonly diagnosed malignant disease, with approximately 951,000 new cases diagnosed and approximately 723,000 cases of mortality each year. The highest mortality rate of GC is in East Asia, and the lowest is in North America. A large number of studies have demonstrated that GC patients are characterized by higher morbidity, metastasis rates, and mortality and lower early diagnosis rates, radical resection rates, and 5-year survival rates. All cases of GC can be divided into two important stages, namely, early- and advanced-stage GC, and the stage mainly determines the treatment strategy for and the therapeutic effect in GC patients. Patients with early-stage GC undergo radical surgery followed by chemotherapy, and the 5-year survival rate can be as high as 90%. However, patients with advanced-stage GC cannot undergo radical surgery because they are at risk for metastasis; therefore, they can choose only radiotherapy or chemotherapy and have a poor prognosis. Based on the lack of specific clinical manifestations and detection methods, most GC patients (>70%) are diagnosed in the advanced stage; therefore, continued efforts toward developing treatments have been focused on advanced-stage GC patients and include molecular targeted therapy, immunotherapy, and small molecular therapy. Nevertheless, in recent years, accumulating evidence has indicated that small molecules, especially long noncoding RNAs (lncRNAs), are involved in the occurrence, development, and progression of GC, and their abundantly dysregulated expression has been identified in GC tissues and cell lines. Therefore, lncRNAs are considered easily detectable molecules and ideal biomarkers or target-specific agents for the future diagnosis or treatment of GC. In this review, we primarily discuss the status of GC, the role of lncRNAs in GC, and the emerging systemic treatments for GC.

show abstract

Section: Treatment Strategies For Gcmentioning

confidence: 99%

[Retracted] Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer

Sun

Jiang

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…GC is characterized by infinitely excessive proliferation and growth of tumor cells (25). Oncogene activation and tumor-suppressor gene inactivation are the main causes of tumorigenesis (26). Traditional treatments for GC include surgery, chemotherapy and radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Knockdown of ST7-AS1 inhibits migration, invasion, cell cycle progression and induces apoptosis of gastric cancer

et al. 2019

View full text Add to dashboard Cite

Role of ST7-AS1 in the malignant progression of gastric cancer (GC) and its molecular mechanisms were investigated. ST7-AS1 level in GC tissues and matched normal tissues was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Its level in GC patients presenting different tumor stages and tumor sizes was determined. Subsequently, ST7-AS1 level in epithelial cells of gastric mucosa and GC cell lines was examined. Cellular behavior of GC cells, including viability, apoptosis, migration, invasion and cell cycle, influenced by ST7-AS1 was evaluated. The interaction between ST7-AS1 and EZH2 was assessed by RNA immunoprecipitation (RIP) assay. The involvement of EZH2 in the progression of GC mediated by ST7-AS1 was identified. ST7-AS1 was upregulated in GC tissues and cell lines. Its level was positively correlated to tumor stage and tumor size of GC. Knockdown of ST7-AS1 attenuated proliferative, migratory and invasive abilities, arrested cell cycle progression and induced apoptosis of GC cells. EZH2 was identified to interact with ST7-AS1, which attenuated the regulatory effects of ST7-AS1 on migratory and invasive abilities of GC cells. Upregulated ST7-AS1 in GC accelerated proliferation, migration and invasion, and inhibited apoptosis, thus aggravating the progression of GC.

show abstract

“…It is known that lncRNAs were widely transcribed in the genome, but our understanding of their functions was limited [7]. Notably, accumulative evidence disclosed the indispensable involvement of lncRNAs in human malignancies in either pro-tumoral or anti-tumor manners [8].…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis

et al. 2020

View full text Add to dashboard Cite

Background: Long non-coding RNAs (lncRNAs) play a vital role in the genesis and development of human cancer. LncRNA MIR99AHG has been reported to be upregulated in acute myeloid leukemia (AML); however, its function in gastric cancer (GC) is still not clear. Here we were aiming to screen the prognostic lncRNA candidates and to explore the function of MIR99AHG in GC. Methods: We have preliminarily screened some candidate lncRNA biomarkers in GC tissues through analyzing microarray datasets. The expression level of MIR99AHG in GC cell lines and tissues was monitored via qPCR. Survival analysis was performed with the patients of our hospital and TCGA database cases. CCK-8 assay, trans-well assay and flow cytometry were performed to determine cell proliferation, invasion, migration and apoptosis. Meanwhile, a target of MIR99AHG was predicted and identified by luciferase reporter gene detection experiments. Results: MIR99AHG was strongly up-regulated in human GC and contributed to cancer progression. Kaplan-Meier analysis revealed that up-regulating MIR99AHG expression was positively correlated with unfavorable overall survival (P < 0.01) of patients from our hospital and TCGA database. Knockdown of MIR99AHG expression inhibited cell proliferation, invasion, migration and promoted cell apoptosis. Moreover, MIR99AHG worked as an oncogenic gene though competing for endogenous RNA (ceRNA) of miR-577. Conclusions: Our findings suggested that MIR99AHG contributes to malignant phenotypes of GC and may become a promising therapeutic target.

show abstract

Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review)

Cited by 23 publications

References 173 publications

[Retracted] Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer

[Retracted] Long Noncoding RNAs: New Regulators of Resistance to Systemic Therapies for Gastric Cancer

Knockdown of ST7-AS1 inhibits migration, invasion, cell cycle progression and induces apoptosis of gastric cancer

Long noncoding RNA MIR99AHG promotes gastric cancer progression by inducing EMT and inhibiting apoptosis via miR577/FOXP1 axis

Contact Info

Product

Resources

About